Skip to main content
. Author manuscript; available in PMC: 2013 Sep 21.
Published in final edited form as: Nature. 2013 Mar 13;495(7441):365–369. doi: 10.1038/nature11929

Figure 2. Non-human primates and healthy human volunteers mobilize HSC/HPC in response to NSAID treatment.

Figure 2

a, Four baboons were treated with G-CSF +/- Meloxicam in a cross-over design and b, CD34+ cells and c, CFU-GM in peripheral blood (PB) determined. d, CD34+ cells and e, CFU-GM in PB determined pre- and post-5 days of meloxicam alone treatment. Seven healthy human volunteers were treated with 15 mg/day p.o. for 5 days, and were assessed for f, CD34+ cells; g, CFU-GM; h, BFU-E, and i, CFU-GEMM pre- and post-treatment. Statistics represent paired, two-tailed t-test.